-89%

est. 2Y upside i

HealthcareSeed

Finding the right cancer drug for each patient.

Rank

#1555

Sector

Biotechnology

Est. Liquidity

~7Y

Data Quality

Data: Low

The equity opportunity at Oncobox is highly speculative due to critically low disclosed funding for a capital-intensive biotech, despite promising scientific validation and a large market opportunity.

Last updated: February 16, 2026

Bull (15%)+500%

Oncobox secures substantial Series A/B funding, achieves key regulatory milestones, and demonstrates strong clinical adoption, leading to a high-multiple exit.

Base (42%)+75%

Oncobox continues scientific development and secures limited partnerships, but struggles to scale due to insufficient funding, resulting in a modest acquisition.

Bear (43%)-100%

Oncobox fails to secure critical follow-on funding, is outmaneuvered by better-resourced competitors, or faces insurmountable regulatory hurdles, leading to company failure.

Est. time to liquidity~7.0 years

Community

Valuation Sentiment

Our model estimates -89% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.